Xin Lang Cai Jing·2025-12-10 01:40Core Viewpoint - Fosun Pharma's stock price increased by 5.96% to HKD 22.76 following the announcement of a licensing agreement with Pfizer for the development of the oral GLP-1 receptor agonist YP05002 [2][6]. Group 1: Licensing Agreement - Fosun Pharma's subsidiary,药友制药, and Fosun Pharma Industry signed a licensing agreement with Pfizer on December 9, 2025, granting Pfizer exclusive rights to develop, use, manufacture, and commercialize YP05002 globally for all human and animal indications [2][6]. - As part of the agreement,药友制药 will receive a non-refundable upfront payment of USD 150 million and up to USD 350 million in milestone payments based on clinical and commercialization progress of the licensed product [2][6]. Group 2: Product Details - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, aimed at treating type 2 diabetes, obesity, and related diseases [3][7]. - The drug works by activating GLP-1 receptors to promote insulin secretion, reduce glucagon secretion, inhibit gastric emptying, and suppress appetite, thereby aiding in weight management and treating metabolic disorders [3][7]. - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [3][7].